GlassScriptPhysician profile
Estuardo E Aroca
NPI 1134133192
$2,549.84
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $456 · 2021: $428 · 2022: $792 · 2023: $487 · 2024: $57.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $521.95 | 2019-2023 | Otezla, Repatha |
| Novo Nordisk INC | $481.59 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $349.23 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $202.96 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $153.83 | 2020-2021 | |
| Glaxosmithkline, LLC. | $143.96 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $117.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $90.59 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.02 | 2020-2021 | |
| Ge Healthcare | $67.26 | 2023 | |
| Dexcom, INC. | $64.91 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $41.51 | 2021-2022 | |
| Abbvie INC. | $39.74 | 2023 | Ubrelvy |
| Abbott Laboratories | $39.26 | 2021-2022 | |
| Exact Sciences Corporation | $22.95 | 2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $22.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.22 | 2019 | |
| Grt US Holding, INC. | $17.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.34 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.27 | 2021 | |
| Allergan, INC. | $13.73 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.33 | 2021 | |
| Daiichi Sankyo INC. | $12.12 | 2021 | |
| Pfizer INC. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Estuardo Aroca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.